Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by Rhumbline Advisers

Rhumbline Advisers increased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 4.1% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 86,730 shares of the medical research company's stock after purchasing an additional 3,405 shares during the quarter. Rhumbline Advisers owned 0.18% of Charles River Laboratories International worth $13,055,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Charles River Laboratories International by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 6,158,926 shares of the medical research company's stock worth $1,136,938,000 after buying an additional 60,497 shares during the last quarter. Wellington Management Group LLP raised its position in Charles River Laboratories International by 9.0% during the fourth quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company's stock worth $752,508,000 after acquiring an additional 335,658 shares during the last quarter. Allspring Global Investments Holdings LLC raised its position in Charles River Laboratories International by 2.7% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company's stock worth $330,231,000 after acquiring an additional 47,221 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Charles River Laboratories International by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 1,233,211 shares of the medical research company's stock valued at $227,042,000 after purchasing an additional 14,787 shares in the last quarter. Finally, Ariel Investments LLC grew its position in shares of Charles River Laboratories International by 18.9% in the fourth quarter. Ariel Investments LLC now owns 1,067,327 shares of the medical research company's stock valued at $197,029,000 after purchasing an additional 169,640 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Citigroup raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and upped their target price for the company from $155.00 to $175.00 in a research note on Tuesday, March 4th. Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating in a research note on Wednesday, May 14th. Mizuho cut their target price on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a research note on Wednesday, April 9th. Robert W. Baird upped their target price on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a report on Thursday, May 8th. Finally, Redburn Atlantic upgraded shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and lowered their price target for the stock from $188.00 to $182.00 in a report on Friday, May 23rd. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $171.85.

Charles River Laboratories International Trading Up 0.6%

Shares of CRL stock traded up $0.84 on Thursday, reaching $151.95. 910,571 shares of the stock were exchanged, compared to its average volume of 998,938. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The stock has a market cap of $7.46 billion, a P/E ratio of 1,013.00, a price-to-earnings-growth ratio of 4.54 and a beta of 1.48. The firm has a 50 day moving average of $128.17 and a two-hundred day moving average of $158.06. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $254.15.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, topping the consensus estimate of $2.06 by $0.28. The company had revenue of $984.17 million during the quarter, compared to analyst estimates of $942.34 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm's revenue was down 2.7% on a year-over-year basis. During the same period in the prior year, the firm posted $2.27 earnings per share. On average, research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the business's stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total transaction of $72,705.00. Following the transaction, the executive vice president now owns 19,513 shares in the company, valued at $2,837,385.33. The trade was a 2.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.30% of the stock is currently owned by corporate insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).